Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) EPS (Weighted Average and Diluted) (2016 - 2025)

Xtant Medical Holdings has reported EPS (Weighted Average and Diluted) over the past 16 years, most recently at $0.0 for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 101.9% to $0.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.0 through Dec 2025, up 100.32% year-over-year, with the annual reading at $0.03 for FY2025, 127.62% up from the prior year.
  • EPS (Weighted Average and Diluted) was $0.0 for Q4 2025 at Xtant Medical Holdings, down from $0.01 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $0.07 in Q3 2023 and troughed at -$0.04 in Q3 2024.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.02 (2021), against an average of -$0.01.
  • Year-over-year, EPS (Weighted Average and Diluted) tumbled 8305.06% in 2022 and then soared 333.33% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.03 in 2021, then soared by 33.33% to -$0.02 in 2022, then tumbled by 50.0% to -$0.03 in 2023, then soared by 33.33% to -$0.02 in 2024, then skyrocketed by 101.9% to $0.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's EPS (Weighted Average and Diluted) are $0.0 (Q4 2025), $0.01 (Q3 2025), and $0.02 (Q2 2025).